A novel resveratrol-curcumin hybrid, a19, attenuates high fat diet-induced nonalcoholic fatty liver disease

Biomed Pharmacother. 2019 Feb:110:951-960. doi: 10.1016/j.biopha.2018.11.088.

Abstract

Both inflammation and fibrosis are essential in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Taking inflammatory cytokines and signaling pathways as vital mediators, the inhibition of inflammation response may be an effective approach for treating NAFLD. a19, a resveratrol-curcumin hybrid, has been confirmed to exhibit a good anti-inflammatory activity by preventing LPS-induced inflammatory response in macrophages. The study aims to evaluate the protective effect of a19 on high fat diet (HFD)-induced NAFLD. In the present study, compound a19 significantly inhibited the HFD-induced lipid accumulation, liver injury, liver inflammation and fibrosis in mouse model. In vitro, a19 obviously suppressed the expression of PA-induced inflammatory cytokines and fibrosis markers mRNA. Meanwhile, the anti-inflammatory effect of a19 was found to be associated with the inhibition of ERK signal pathway. These results indicated that a19 can be potentially used as a protective agent for NAFLD.

Keywords: Anti-inflammation; Curcumin; Fibrosis; Non-alcoholic fatty liver disease; Resveratrol.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Curcumin / administration & dosage*
  • Diet, High-Fat / adverse effects*
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Hep G2 Cells
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / etiology*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Resveratrol / administration & dosage*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Drug Combinations
  • Curcumin
  • Resveratrol